Kim et al., demonstrated that patients with stage III GC and negative BRCA1 nuclear expression saw a significant increase in OS and DFS when given a fluoropyrimidine combined with platinum-based adjuvant chemotherapy compared to patients with positive BRCA1 nuclear expression [34]. The gene discussed is BRCA1; the disease is gastric cancer.